Vericel Corp (NAS:VCEL)
$ 51.53 0.4 (0.78%) Market Cap: 2.50 Bil Enterprise Value: 2.49 Bil PE Ratio: 9,999.00 PB Ratio: 10.68 GF Score: 79/100

Vericel Corp at Needham Growth Conference Transcript

Jan 15, 2020 / 07:10PM GMT
Release Date Price: $17 (+3.09%)
Gerard Michel
Vericel Corporation - CFO & VP, Corporate Development

Thank you very much. I am the CFO of Vericel. I'm pleased to be here. Our CEO, Nick Colangelo, would have loved to have been here. As many of you know, there's a large healthcare conference going on the West Coast, San Francisco, right now. So we've divided and conquered. I flew in on the redeye last night. I'm joined by our COO, Mike Halpin, in the back. So thrilled to be here and tell you a little bit about Vericel.

Before we do so, I'll go through the typical Safe Harbor statement. So forward-looking statements will not necessarily be updated and you should look at our SEC filings for further information.

All right, so Vericel is a leader in the advanced therapies for the sports medicine and severe burn care markets. The Company is built around the highly innovative advanced cell therapy platform. We have two commercial franchises, sports medicine, as I mentioned and Epicel. Those are both autologous cell therapy products. They are regulated as combined biologic device products with the biological component

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot